26 related articles for article (PubMed ID: 38513466)
1. RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.
Loi S; Dushyanthen S; Beavis PA; Salgado R; Denkert C; Savas P; Combs S; Rimm DL; Giltnane JM; Estrada MV; Sánchez V; Sanders ME; Cook RS; Pilkinton MA; Mallal SA; Wang K; Miller VA; Stephens PJ; Yelensky R; Doimi FD; Gómez H; Ryzhov SV; Darcy PK; Arteaga CL; Balko JM
Clin Cancer Res; 2016 Mar; 22(6):1499-509. PubMed ID: 26515496
[TBL] [Abstract][Full Text] [Related]
2. Comparison of PD-L1 (22C3) Expression in Paired Primary and Metastatic Breast Carcinoma.
Huang X; Anderson SA; Siegal GP; Wei S; Liu S; Yang J; Roisin P; Pickens JT; Huo L; Sahin AA; Granada CP; Chen S
Clin Breast Cancer; 2024 Jun; 24(4):e310-e318. PubMed ID: 38492995
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 Immunohistochemical Expression in Endometrial Carcinoma: Egyptian Cross-Sectional Study.
Wahba MG; Soliman SS; Salama ME; Nasr S; Al Shereef ZAE
Asian Pac J Cancer Prev; 2024 Apr; 25(4):1441-1450. PubMed ID: 38680006
[TBL] [Abstract][Full Text] [Related]
4. The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumab.
Buisseret L; Bareche Y; Venet D; Girard E; Gombos A; Emonts P; Majjaj S; Rouas G; Serra M; Debien V; Agostinetto E; Garaud S; Willard-Gallo K; Larsimont D; Stagg J; Rothé F; Sotiriou C
ESMO Open; 2024 May; 9(5):102964. PubMed ID: 38703428
[TBL] [Abstract][Full Text] [Related]
5. Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1.
Li CW; Lim SO; Chung EM; Kim YS; Park AH; Yao J; Cha JH; Xia W; Chan LC; Kim T; Chang SS; Lee HH; Chou CK; Liu YL; Yeh HC; Perillo EP; Dunn AK; Kuo CW; Khoo KH; Hsu JL; Wu Y; Hsu JM; Yamaguchi H; Huang TH; Sahin AA; Hortobagyi GN; Yoo SS; Hung MC
Cancer Cell; 2018 Feb; 33(2):187-201.e10. PubMed ID: 29438695
[TBL] [Abstract][Full Text] [Related]
6. Role of SOX10 Immunohistochemical Expression in Diagnosing Triple Negative Breast Cancer and Its Correlation With Clinicopathological Features.
Tariq MU; Siddiqui MA; Ud Din N; Kayani N
Cureus; 2024 Apr; 16(4):e59276. PubMed ID: 38813332
[TBL] [Abstract][Full Text] [Related]
7. The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practice.
Gonzalez-Ericsson PI; Stovgaard ES; Sua LF; Reisenbichler E; Kos Z; Carter JM; Michiels S; Le Quesne J; Nielsen TO; Laenkholm AV; Fox SB; Adam J; Bartlett JM; Rimm DL; Quinn C; Peeters D; Dieci MV; Vincent-Salomon A; Cree I; Hida AI; Balko JM; Haynes HR; Frahm I; Acosta-Haab G; Balancin M; Bellolio E; Yang W; Kirtani P; Sugie T; Ehinger A; Castaneda CA; Kok M; McArthur H; Siziopikou K; Badve S; Fineberg S; Gown A; Viale G; Schnitt SJ; Pruneri G; Penault-Llorca F; Hewitt S; Thompson EA; Allison KH; Symmans WF; Bellizzi AM; Brogi E; Moore DA; Larsimont D; Dillon DA; Lazar A; Lien H; Goetz MP; Broeckx G; El Bairi K; Harbeck N; Cimino-Mathews A; Sotiriou C; Adams S; Liu SW; Loibl S; Chen IC; Lakhani SR; Juco JW; Denkert C; Blackley EF; Demaria S; Leon-Ferre R; Gluz O; Zardavas D; Emancipator K; Ely S; Loi S; Salgado R; Sanders M;
J Pathol; 2020 Apr; 250(5):667-684. PubMed ID: 32129476
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 (SP142) Expression in Primary and Recurrent/Metastatic Triple-Negative Breast Cancers and Its Clinicopathological Significance.
Han EK; Woo JW; Suh KJ; Kim SH; Kim JH; Park SY
Cancer Res Treat; 2024 Apr; 56(2):557-566. PubMed ID: 38097920
[TBL] [Abstract][Full Text] [Related]
9. Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms.
Sigurjonsdottir G; De Marchi T; Ehinger A; Hartman J; Bosch A; Staaf J; Killander F; Niméus E
Breast Cancer Res; 2023 Oct; 25(1):123. PubMed ID: 37817263
[TBL] [Abstract][Full Text] [Related]
10. PD-L1 expression in tumor infiltrated lymphocytes predicts survival in triple-negative breast cancer.
Wang X; Liu Y
Pathol Res Pract; 2020 Mar; 216(3):152802. PubMed ID: 32005408
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
[TBL] [Abstract][Full Text] [Related]
12. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K
Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236
[TBL] [Abstract][Full Text] [Related]
13. Histological subtype is associated with PD-L1 expression and CD8+ T-cell infiltrates in triple-negative breast carcinoma.
Salisbury T; Abozina A; Zhang C; Mao E; Banyi N; Leo J; Ionescu D; Zhou C; Wang G
Ann Diagn Pathol; 2022 Apr; 57():151901. PubMed ID: 35091156
[TBL] [Abstract][Full Text] [Related]
14. Assessing the relationship between tumor-infiltrating lymphocytes and PD-L1 expression in triple negative breast cancer: Identifying optimal TILs cut-off value for pathologic reporting.
Suwannaphoom K; Soontornsit S; Wiwatwarayos K; Seneetuntigul P; Julimasart P
Ann Diagn Pathol; 2024 Jun; 70():152294. PubMed ID: 38513466
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
